TAGLN Antibody

What is TAGLN/Transgelin and why is it important as a research target?

TAGLN (also known as SM22-alpha) is an actin cross-linking/gelling protein involved in calcium interactions and contractile properties of cells that may contribute to replicative senescence . It is abundantly expressed in visceral and vascular smooth muscle cells and serves as an early marker of smooth muscle differentiation . Beyond its traditional role as a smooth muscle marker, TAGLN has gained research importance due to its expression in brain pericytes (relevant for blood-brain barrier studies) , altered expression in multiple cancer types (colorectal, breast, prostate cancer, and glioblastoma) , and presence in endothelial cells undergoing morphological changes during angiogenesis .

How do I choose the appropriate TAGLN antibody for my specific application?

Selection should be guided by several experimental factors:

• Application compatibility: Different antibodies are optimized for specific applications. For example:

  • For Western blotting: Most antibodies are validated, with recommended dilutions typically around 1:1000

  • For Immunohistochemistry: Select antibodies validated for IHC-P with proven reactivity in your target tissue

  • For Immunofluorescence: Verify antibodies are validated for IF/ICC applications

• Species reactivity: Confirm the antibody's reactivity with your target species. Some antibodies are species-specific, while others show cross-reactivity:

  • Human-specific: ab233971

  • Human/Mouse/Rat cross-reactive: MAB7886, A03962-2

• Isoform specificity: Be aware that standard anti-TAGLN antibodies may recognize multiple TAGLN isoforms (TAGLN1/2/3) . If isoform specificity is critical, perform validation experiments or select antibodies with confirmed specificity.

What are the optimal conditions for Western blotting with TAGLN antibodies?

Based on validated protocols from multiple sources:

• Sample preparation:

  • Use human aorta, uterus, or smooth muscle tissues as positive controls

  • For cell lines, MCF 10A (human breast epithelial cells) show detectable TAGLN expression

• Separation conditions:

  • Use reducing conditions for optimal results

  • Expected molecular weight: 16-25 kDa (typically 22-24 kDa)

• Antibody dilutions and detection:

  • Primary antibody: 0.5-5 μg/mL or 1:1000 dilution

  • Secondary antibody: HRP-conjugated anti-species IgG (e.g., Anti-Mouse IgG for MAB78861)

  • Buffer recommendation: Immunoblot Buffer Group 1 has been validated with multiple antibodies

How should I optimize immunofluorescence staining with TAGLN antibodies?

For optimal immunofluorescence results:

• Sample preparation:

  • Fixation: Immersion fixation works well for cell lines

  • For tissue sections: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is recommended

• Staining protocol:

  • Primary antibody concentration: 5-10 μg/mL

  • Incubation: 3 hours at room temperature or overnight at 4°C

  • Secondary detection: Fluorophore-conjugated secondary antibodies work well (e.g., NorthernLights™ 557-conjugated Anti-Mouse IgG)

  • Counterstain: DAPI for nuclear visualization

• Expected staining pattern:

  • Primarily cytoplasmic localization

  • In some contexts, partial colocalization with actin filaments, especially at cell periphery

  • In cancer cells, potential nuclear localization has been reported

How can I differentiate between TAGLN isoforms (TAGLN1/2/3) in my experiments?

This requires careful experimental design as standard antibodies may recognize multiple isoforms:

• Combined approach strategy:

  • Use qPCR with isoform-specific primers to determine mRNA expression of each isoform

• Validation approach:

  • Use gene knockdown/knockout strategies with isoform-specific siRNAs to validate antibody specificity

• Western blot interpretation caution:

  • When using anti-TAGLN antibodies that recognize multiple isoforms, verify results with complementary approaches

  • In knockout validation experiments, deletion of any single isoform may show decreased signal intensity

What are the known technical challenges when using TAGLN antibodies in cancer research?

Several considerations specific to cancer research applications:

• Expression variability:

  • TAGLN expression is context-dependent in cancers, with reports of both up- and down-regulation depending on cancer type and stage

  • Validation in specific cancer models is essential as expression patterns may differ from normal tissues

• Subcellular localization differences:

  • In cancer cells, TAGLN may localize to both cytoplasm and nucleus, unlike its primarily cytoplasmic localization in smooth muscle cells

  • When analyzing cancer samples, use confocal microscopy to accurately determine subcellular localization

• Functional analysis challenges:

  • For mechanistic studies in cancer cells, combining TAGLN antibody staining with markers of relevant pathways is recommended

  • In glioblastoma stem cells (GSCs), TAGLN forms regulatory feedforward circuits with HIF1α in hypoxic responses, requiring careful experimental design for pathway analyses

How can TAGLN antibodies be utilized in angiogenesis and vascular biology research?

TAGLN has emerging roles in endothelial cell biology during angiogenesis:

• 3D culture models:

  • TAGLN expression increases in endothelial cells cultured in 3D sandwich systems compared to 2D cultures

  • In sprouting assays, TAGLN protein partially colocalizes with actin filaments, especially at cell periphery

• Experimental approach for angiogenic studies:

  • Culture endothelial cells (e.g., HUVECs) as spheroids in type I collagen gel to induce sprouting

  • Perform immunofluorescence with anti-TAGLN antibodies (10 μg/mL) along with endothelial markers (VE-cadherin) and actin visualization

  • Consider triple staining (TAGLN, VE-cadherin, actin) for comprehensive analysis of morphological changes

• Functional analysis through gene modification:

  • Single and triple knockout of TAGLN isoforms in endothelial cells can be used to study their roles in cord-like structure formation

  • CRISPR/Cas9 system has been successfully employed for generating TAGLN isoform knockout endothelial cells

What are the best practices for using TAGLN antibodies in studying the hypoxic responses of cancer stem cells?

For researchers investigating TAGLN in cancer stem cell biology:

• Experimental models:

  • Patient-derived glioblastoma stem cells (GSCs) cultured under hypoxic conditions show TAGLN dependency

  • Sphere formation assays can be used to assess the impact of TAGLN on cancer stem cell self-renewal

• Mechanistic studies approach:

  • Combine TAGLN antibody staining with analysis of:

    • Hypoxia markers (HIF1α, CA9)

    • Stem cell markers (SOX2, OLIG2)

    • Differentiation markers (GFAP)

    • Proliferation markers (Ki67, EdU incorporation)

    • Apoptotic markers (Cleaved Caspase3, Cleaved PARP)

• Protein interaction analysis:

  • Co-immunoprecipitation (Co-IP) experiments can reveal interactions between TAGLN and other proteins (e.g., HIF1α, HDAC2)

  • ChIP-seq approaches can identify TAGLN binding to promoter regions of target genes (e.g., HIF1A)

What are appropriate positive and negative controls for TAGLN antibody experiments?

For reliable interpretation of TAGLN antibody results:

• Positive tissue/cell controls:

  • Tissues: Human/mouse/rat aorta, uterus, and smooth muscle tissues

  • Cell lines: MCF 10A (human breast epithelial cells)

  • Primary cells: Vascular and visceral smooth muscle cells

• Knockout/knockdown validation:

  • Genetic approaches: CRISPR/Cas9-mediated knockout of TAGLN

• Blocking peptide controls:

  • For antibodies where blocking peptides are available, pre-incubation of the antibody with excess immunizing peptide should abolish specific staining

How can I address potential cross-reactivity issues with TAGLN antibodies?

To ensure specificity of TAGLN antibody signals:

• Isoform cross-reactivity assessment:

  • Standard anti-TAGLN antibodies may recognize all three TAGLN isoforms

  • Use isoform-specific gene knockout or knockdown to determine specificity

  • Combine protein detection with qPCR for isoform-specific mRNA quantification

• Species cross-reactivity considerations:

  • When working across species, verify reactivity with each species individually

  • Human/mouse/rat cross-reactive antibodies have been validated for multiple applications

• Technical validation approaches:

  • Use multiple antibodies targeting different epitopes of TAGLN

  • Include appropriate negative controls (tissues/cells known not to express TAGLN)

  • For critical experiments, confirm results with multiple detection methods (e.g., immunoblotting and immunofluorescence)

How are TAGLN antibodies being utilized in blood-brain barrier research?

Recent developments in this field include:

• Pericyte identification and characterization:

  • TAGLN expression has been detected in brain pericytes, providing utility in studying the blood-brain barrier

  • Immunostaining with TAGLN antibodies can help identify pericytes in neurovascular unit studies

  • Co-staining with endothelial markers helps distinguish pericytes from endothelial cells in brain vasculature

• Methodological approach:

  • For brain sections, use heat-mediated antigen retrieval with EDTA buffer (pH 8.0)

  • Combined staining with endothelial markers (CD31, VE-cadherin) and pericyte markers (PDGFRβ, NG2) allows comprehensive analysis of neurovascular units

  • For quantitative analysis, confocal microscopy with z-stack imaging is recommended for accurate colocalization assessment

What novel insights have emerged from studying TAGLN's role in cancer progression using antibody-based approaches?

Recent findings highlight complex roles of TAGLN in cancer:

• Glioblastoma stem cell regulation:

  • TAGLN forms a regulatory feedforward circuit with HIF1α to support hypoxic responses of glioblastoma stem cells

  • Mechanistically, TAGLN stabilizes HDAC2 to deacetylate p53 and maintains GSC self-renewal under hypoxia

  • Targeting TAGLN/HDAC2-p53 pathway disrupts GSC maintenance

• Methodological innovations:

  • Combined ChIP-seq and co-immunoprecipitation approaches reveal TAGLN binding to promoter regions of target genes (e.g., HIF1A)

  • Multiple Em for motif elicitation analysis shows enrichment of elements within TAGLN-binding sites

  • In vivo tumor initiation assays with TAGLN-targeted cells provide gold standard evidence for cancer stem cell dependency

• Integrated experimental approach:

  • Combined use of in vitro assays (sphere formation, EdU incorporation) with in vivo tumor models

  • Correlation of TAGLN expression with clinical parameters and patient outcomes

  • Multi-marker analysis (GSC markers, proliferation markers, apoptotic markers) for comprehensive phenotypic characterization